Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling

Journal of Cardiology

Volumn 58, Issue 2, 2011, Pages 131-136

  Kato, Takeshi ^a,b   Yamashita, Takeshi ^a   Sekiguchi, Akiko ^a   Tsuneda, Takayuki ^a   Sagara, Kouichi ^a   Takamura, Masayuki ^b   Kaneko, Shuichi ^b   Aizawa, Tadanori ^a   Fu, Long Tai ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiotensin II; Arrhythmias; Atrial fibrillation; Diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CANDESARTAN; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; HEMOGLOBIN A1C; STREPTOZOCIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FUNCTION; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSMOTIC PUMP; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIGENS, NEOPLASM; ARRHYTHMIAS, CARDIAC; BENZIMIDAZOLES; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; FIBROSIS; HEART ATRIA; MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

EID: 80052031457     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.06.003     Document Type: Article

References (32)

1. Watanabe H., Tanabe N., Watanabe T., Darbar D., Roden D.M., Sasaki S., Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008, 117:1255-1260.
2. Korantzopoulos P., Kokkoris S., Papaioannides D. The association of metabolic syndrome with atrial fibrillation: an emerging epidemiological and pathophysiological hypothesis. Cardiology 2005, 104:148-149.
3. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
4. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98:476-484.
5. Movahed M.R., Hashemzadeh M., Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005, 105:315-318.
6. Ostgren C.J., Merlo J., Rastam L., Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004, 6:367-374.
7. Shigematsu Y., Hamada M., Nagai T., Nishimura K., Inoue K., Suzuki J., Ogimoto A., Higaki J. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011, (April). [Epub ahead of print].
8. Corley S.D., Epstein A.E., DiMarco J.P., Domanski M.J., Geller N., Greene H.L., Josephson R.A., Kellen J.C., Klein R.C., Krahn A.D., Mickel M., Mitchell L.B., Nelson J.D., Rosenberg Y., Schron E., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509-1513.
9. Klem I., Wehinger C., Schneider B., Hartl E., Finsterer J., Stollberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev 2003, 19:320-328.
10. Yamashita T. Frontiers of anticoagulation therapy for atrial fibrillation. J Cardiol 2011, (April). [Epub ahead of print].
11. Lip G.Y., Varughese G.I. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005, 105:319-321.
12. Kato T., Yamashita T., Sekiguchi A., Sagara K., Takamura M., Takata S., Kaneko S., Aizawa T., Fu L.T. What are arrhythmogenic substrates in diabetic rat atria?. J Cardiovasc Electrophysiol 2006, 17:890-894.
13. Kato T., Yamashita T., Sekiguchi A., Tsuneda T., Sagara K., Takamura M., Kaneko S., Aizawa T., Fu L.T. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008, 19:415-420.
14. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., Ishikawa N., Nangaku M., Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002, 13:2478-2487.
15. Nangaku M., Miyata T., Sada T., Mizuno M., Inagi R., Ueda Y., Ishikawa N., Yuzawa H., Koike H., van Ypersele de Strihou C., Kurokawa K. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003, 14:1212-1222.
16. Forbes J.M., Cooper M.E., Thallas V., Burns W.C., Thomas M.C., Brammar G.C., Lee F., Grant S.L., Burrell L.M., Jerums G., Osicka T.M. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002, 51:3274-3282.
17. Yamagishi S., Takeuchi M., Matsui T., Nakamura K., Imaizumi T., Inoue H. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005, 579:4265-4270.
18. Fujita M., Okuda H., Tsukamoto O., Asano Y., Hirata Y.L., Kim J., Miyatsuka T., Takashima S., Minamino T., Tomoike H., Kitakaze M. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:e138-e142.
19. Lee C.I., Guh J.Y., Chen H.C., Hung W.C., Yang Y.L., Chuang L.Y. Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells. J Cell Biochem 2005, 95:281-292.
20. Tojo A., Onozato M.L., Kurihara H., Sakai T., Goto A., Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003, 26:413-419.
21. Stevens V.J., Vlassara H., Abati A., Cerami A. Nonenzymatic glycosylation of hemoglobin. J Biol Chem 1977, 252:2998-3002.
22. Day J.F., Thornburg R.W., Thorpe S.R., Baynes J.W. Nonenzymatic glucosylation of rat albumin. Studies in vitro and in vivo. J Biol Chem 1979, 254:9394-9400.
23. Schnider S.L., Kohn R.R. Glucosylation of human collagen in aging and diabetes mellitus. J Clin Invest 1980, 66:1179-1181.
24. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., Wang F., Pan Y.C., Tsang T.C., Stern D. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997.
25. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004.
26. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814.
27. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997, 272:16498-16506.
28. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998, 41:1435-1441.
29. Tsuji H., Iehara N., Masegi T., Imura M., Ohkawa J., Arai H., Ishii K., Kita T., Doi T. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 1998, 245:583-588.
30. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
31. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84:489-497.
32. Greten J., Kreis I., Wiesel K., Stier E., Schmidt A.M., Stern D.M., Ritz E., Waldherr R., Nawroth P.P. Receptors for advance glycation end-products (AGE) - expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996, 11:786-790.